People living with HIV do not have a major or lesser threat of severe COVID-19 than the general population and deserve to obtain a similar treatment method, according to a study published in The Lancet HIV.
People living with HIV (HIV) “deserve not to be considered opposed to SARS-CoV-2 infection or who have a lower threat of serious disease,” Pilar Vizcarra, MD, from the Department of Infectious Diseases at Ramón y Cajal University. Hospital in Madrid, says Healio. “Special attention should be paid to others with comorities or a low number of CD4 cells that may have higher grades of COVID-19 or worse results.”
Vizcarra and his colleagues conducted a prospective observational examination of 51 HIV-positive patients with a suspected COVID-19 or shown admitted to a singles hospital in Madrid. The clinical characteristics of PATIENTS with COVID-19 and HIV are shown with those of 1,288 HIV-positive patients who did not have COVID-19 and were tested prior to the pandemic.
Overall, 69% of co-infection cases referred to laboratory-confirmed COVID-19 patients, 55% of whom had to be hospitalized. CD4 counts were in either group, but 63% of patients with COVID-19 and HIV had at least a comorability, compared to 38% of patients without COVID-19.
A total of 12% of patients were seriously ill, two had CD4 grades below two hundred L-compatible cells, and 4% died.
“Our effects help the concept that PHA have a COVID-19 infection rate similar to that of the general population,” Vizcarra said. “In addition, clinical, biological and radiographic characteristics were comparable to those reported in unedified individuals. Therefore, PHA deserves advantages from a similar remedy approach.”
Vizcarra wished for more studies and noted several limitations of the study.
“While we include all 5Ms diagnosed with COVID-19 at the time of the test, we still reported a small number of patients, restricting generalization of results,” he said. “In addition, local recommendations limited the use of confirmation tests to others with admission criteria, which may have skewed the COVID-19 diagnosis rate. Other multicenter studies with knowledge of seroprevalence would yield our results.”
Get the latest news and in your inbox
© 2020 Healio All rights reserved.
Get the latest news and in your inbox
© 2020 Healio All rights reserved.